Effect of dialyzer membrane materials on survival in chronic hemodialysis patients: Results from the annual survey of the Japanese Nationwide Dialysis Registry

Masanori Abe1*, Takayuki Hamano2, Atsushi Wada3, Shigeru Nakai4, Ikuto Masakane5, on behalf of the Renal Data Registry Committee, Japanese Society for Dialysis Therapy

1 Division of Nephrology, Hypertension and Endocrinology, Nihon University School of Medicine, Tokyo, Japan, 2 Department of Comprehensive Kidney Disease Research, Osaka University Graduate School of Medicine, Osaka, Japan, 3 Department of Nephrology, Kitasaito Hospital, Asahikawa, Japan, 4 Department of Clinical Engineering, Fujita Health University, Aichi, Japan, 5 Yabuki Hospital, Yamagata, Japan

* Current address: Division of Nephrology, Hypertension and Endocrinology, Department of Internal Medicine, Nihon University School of Medicine, Tokyo, Japan

¶ Membership of the Japanese Society for Dialysis Therapy is listed in the Acknowledgments.

Abstract

Background
Little information is available regarding which type of dialyzer membrane results in good prognosis in patients on chronic hemodialysis. Therefore, we conducted a cohort study from a nationwide registry of hemodialysis patients in Japan to establish the association between different dialyzer membranes and mortality rates.

Methods
We followed 142,412 patients on maintenance hemodialysis (female, 39.1%; mean age, 64.8 ± 12.3 years; median dialysis duration, 7 [4–12] years) for a year from 2008 to 2009. We included patients treated with seven types of high-flux dialyzer membranes at baseline, including cellulose triacetate (CTA), ethylene vinyl alcohol (EVAL), polyacrylonitrile (PAN), polyester polymer alloy (PEPA), polyethersulfone (PES), polymethylmethacrylate (PMMA), and polysulfone (PS). Cox regression was used to estimate the association between baseline dialyzers and all-cause mortality as hazard ratios (HRs) and 95% confidence intervals for 1-year mortality adjusting for potential confounders, and propensity score matching analysis was performed.

Results
The distribution of patients treated with each membrane was as follows: PS (56.0%), CTA (17.3%), PES (12.0%), PEPA (7.5%), PMMA (4.9%), PAN (1.2%), and EVAL (1.1%). When data were adjusted using basic factors, with PS as a reference group, the mortality rate was significantly higher in all groups except for the PES group. When data were further adjusted for dialysis-related factors, HRs were significantly higher for the CTA, EVAL, and PEPA.
groups. When the data were further adjusted for nutrition-and inflammation-related factors, HRs were significantly lower for the PMMA and PES groups compared with the PS group. After propensity score matching, HRs were significantly lower for the PMMA group than for the PS group.

**Conclusion**

The results suggest that the use of different membrane types may affect mortality in hemodialysis patients. However, further long-term prospective studies are needed to clarify these findings, including whether the use of the PMMA membrane can improve prognosis.

**Introduction**

Dialyzer technology is undergoing development and moving towards high permeability and biocompatibility; therefore, there is an urgent need for robust evidence regarding the performance of various types of dialyzers. Dialyzers are classified into two types, low-flux and high-flux membrane dialyzers. High-flux dialyzers are recommended for good outcomes in hemodialysis patients [1,2]. The Kidney Disease Outcomes Quality Initiative guidelines discourage the use of cellulose membranes with poor biocompatibility [3]. The European Renal Best Practice guidelines recommend the use of high-flux membranes with large pores and high biocompatibility to improve morbidity and mortality [4]. Low-flux dialyzers are defined by an ultrafiltration rate $<15$ mL/mmHg/h and $\beta_2$-microglobulin ($\beta_2$M) clearance $<15$ mL/min, while high-flux dialyzers are defined by an ultrafiltration rate $\geq15$ mL/mmHg/h and $\beta_2$M clearance $\geq15$ mL/min [1]. However, in Japan before 2016, dialyzers were classified from types I to V based on their $\beta_2$M clearance of $<10$, $<30$, $<50$, and $>70$ mL/min, respectively, at a blood flow rate of 200 mL/min and a dialysate flow rate of 500 mL/min [5]. Type II to V dialyzers are classified as high-flux membranes; only type I dialyzers are classified as low-flux membranes. High-performance membrane (HPM) dialyzers are quickly becoming conventional in Japan, but this is not the case in other countries. Moreover, the selection criteria for dialyzer membranes in the Japanese guidelines differ distinctly from those used in other countries [1]. The main purpose of HPMs is to eliminate uremic substances with molecular weights of 10,000–30,000 Da. The HPM concept, therefore, comprises all of the following characteristics: (1) high hydraulic permeability; (2) high solute permeability, especially for “middle molecules”; and (3) high biocompatibility [5]. In particular, types IV and V, which are classified as HPM dialyzers and composed of synthetic membranes, are used for $>90\%$ of Japanese hemodialysis patients [1]. Therefore, many Japanese patients are currently treated with HPM dialyzers, including high-flux membrane dialyzers. Furthermore, several different membrane materials are used in HPM dialyzers. However, there is little information available regarding which type of membrane results in good prognosis. Therefore, we conducted a cohort study from a nationwide registry of hemodialysis patients in Japan to clarify the association between different HPM dialyzers and mortality rates.
Subjects and methods
The protocol of this study was approved by the Ethics Committee of the JSDT (JRDR-SAF-15009), and all procedures fully adhered to the Declaration of Helsinki. The study was registered with the University Hospital Medical Information Network (UMIN000018641).

Database creation
The data were obtained from annual nationwide surveys of dialysis patients, which comprise the Japanese Renal Data Registry (JRDR) system, conducted by the Japanese Society for Dialysis Therapy (JSDT). The JSDT has been conducting an annual questionnaire survey of dialysis facilities throughout Japan since 1968, and several papers based on these surveys have been published [6–9]. Since 1983, the JSDT has been compiling a computer-based registry. Details regarding the inception, limitations, validity, variables, and questionnaires used in the study are available online at the JSDT homepage, (http://www.jsdt.or.jp). Year-end survey questionnaires are sent to all dialysis facilities in Japan each year. The questionnaires are administered by volunteers from among the doctors and staff of the facilities, the principal investigators in each prefecture, and JSDT committee members. In addition to the regular questionnaire, new survey items are added each year. In 2008, new questions were added regarding the dialyzers used. Data covered 282,622 patients undergoing dialysis at 4,072 facilities in the 2008 survey, and 290,675 patients at 4,125 facilities in the 2009 survey [10,11]. The study population consisted of patients who underwent maintenance dialysis between December 2008 and December 2009. We included patients who underwent maintenance hemodialysis 3 times a week, who had received maintenance dialysis for at least 2 years at the end of the year 2008 and were treated with one of the seven major dialyzers, namely, cellulose triacetate (CTA), ethylene vinyl alcohol (EVAL), polyacrylonitrile (PAN), polyester polymer alloy (PEPA), polyethersulfone (PES), polymethylmethacrylate (PMMA), and polysulfone (PS) membranes (S1 and S2 Tables). Patients were followed for outcomes through 31 December 2009 and 1-year all-cause mortality was analyzed retrospectively. We excluded patients who had been dialyzed fewer than 3 times a week or fewer than 2 h per treatment, those who had been treated with dialyzers other than the abovementioned seven dialyzers, those who had received peritoneal dialysis, those with a history of organ transplantation, those aged <20 years, and those whose records covering date of birth, dialysis initiation, or outcomes were incomplete.

Blood samples were drawn and analyzed at each dialysis center, typically within 24 h of the sample being taken. The most recent values, including serum albumin, hemoglobin, calcium, phosphate, total cholesterol, C-reactive protein (CRP), β2M, adequacy of dialysis treatment (single-pool Kt/V), normalized protein catabolic rate (nPCR), and % creatinine generation rate (%CGR) at the time of the survey were collected. These variables were measured at least monthly in many facilities because doing so is recommended by the JSDT guidelines [1]. Overall, 263,024 patients were registered at the end of year 2008. After exclusions, 142,412 patients remained (Fig 1). Demographic data and details of medical history were collected, with information on age, sex, dialysis duration, primary diseases of end-stage kidney disease, height, post-dialysis body weight, types of dialyzers, and history of vascular complications (cerebral infarction, cerebral hemorrhage, myocardial infarction, or limb amputation). Outcomes were examined at the end of 2009 using the JSDT 2009 database ID number and other pertinent identifiers to determine outcome such as death, kidney transplantation, and withdrawal from the registry.
Statistical methods

Data were summarized using proportions, with mean ± standard deviation or median [interquartile range] as appropriate. Categorical variables were analyzed using the chi-square test, and continuous variables were compared using the *t*-test, as appropriate. Categorical data were compared between groups by using repeated-measures analysis of variance and Tukey’s honestly significant difference test or the Kruskal–Wallis test, as appropriate. Laboratory data were refined using these limits: height, 120–200 cm; body weight, 20–150 kg; albumin, 1.0–5.5 g/dL; hemoglobin, 5.0–20.0 g/dL; Kt/V, 0.5–4.0; and nPCR, 0.3–2.0.

Outcome analysis by basic factors, dialysis dose, and nutrition factors

Survival analyses with Cox proportional hazards regression model were used to examine whether baseline basic factors including age, sex, dialysis duration, and presence or absence of diabetes and cardiovascular comorbidity predicted survival for up to 1 year of follow-up. We divided patients into seven a priori categories based on dialysis duration (2 to <5, 5 to <10, 10 to <15, 15 to <20, 20 to <25, 25 to <30, and ≥30 years) to examine the dose–response association between dialysis duration categories and death risk. Additional analyses were performed and adjusted for dialysis-related factors such as dialysis dose as assessed by Kt/V, and high- or low-flux membranes. We divided patients into eight a priori categories based on single-pool Kt/V: <0.8 and ≥2.0, with increments of 0.2 in between, to examine the dose–response association between Kt/V categories and death risk. Each dialyzer was divided into two types.
according to criteria for high-flux (β2M clearance ≥15 mL/min and ultrafiltration rate ≥15 mL/mmHg/h) and for low-flux membranes (β2M clearance <15 mL/min and ultrafiltration rate <15 mL/mmHg/h). Additional analyses were performed with adjustment for nutrition and inflammation factors, including serum albumin values, hemoglobin levels, total cholesterol values, body mass index (BMI), nPCR, %CGR, and CRP levels. To examine the dose-response associations between these categories and death risk, we divided patients into six a priori categories based on nPCR <0.5 and ≥1.3 g/kg/day, with increments of 0.2 g/kg/day in between; serum albumin <3.0 and ≥4.5 g/dL, with increments of 0.5 g/dL in between; calcium adjusted for serum albumin <8.5 and ≥10.5 mg/dL, with increments of 1.0 mg/dL in between; phosphate <3.5 and ≥8.5 mg/dL, with increments of 1.0 mg/dL in between; total cholesterol <80 and ≥240 mg/dL, with increments of 40 mg/dL in between; BMI: <16 and ≥28 kg/m², with increments of 2 kg/m² in between; and %CGR: <60% and ≥130%, with increments of 10% in between [12–15]. Age, CRP levels, and hemoglobin levels were analyzed as continuous variables.

Outcome analysis by seven types of dialyzer membranes

Survival analyses with Cox proportional hazards regression were used to examine whether different types of dialyzer membranes predicted survival for up to 1 year of follow-up. The final analysis examined the associations between types of dialyzer membranes and all-cause mortality. We divided the patients into seven groups based on which dialyzer membrane was used. Models were analyzed when adjusted for the abovementioned basic factors, dialysis dose, and nutritional- and inflammation-factors measured at the study baseline (S1 File). The PS group was defined as the reference group because it is the most widely used dialyzer worldwide.

To reduce potential confounding and treatment selection bias, we adjusted the significant difference in baseline covariates by propensity score matching. We calculated the propensity score for factors contributing to mortality including the abovementioned basic factors, dialysis dose, and nutritional- and inflammation factors, which were examined using univariate Cox proportional hazards regression analysis. The score was then used to match patients in the PS group as a reference with patients in the other membrane groups in a 1:1 ratio, resulting in 10,592, 571, 764, 4,683, 7,480, and 3,835 matched pairs (CTA, EVAL, PAN, PEPA, PES, and PMMA membranes, respectively). Moreover, all-cause mortality was compared for propensity score-matched patients.

Missing covariate data were imputed by the conventional method for multivariate regression as appropriate. For all analyses, results were considered statistically significant if P < 0.05. All analyses were carried out using JMP® version 13.0 (SAS Institute, Cary, NC).

Results

Study characteristics

The baseline characteristics of the patients in our cohort are shown in Table 1. In this cohort, which comprised 142,412 patients, average values were as follows: age, 64.8 ± 12.3 years; dialysis duration, 7 [4–12] years; female patients, 39.1%; BMI, 21.1 ± 3.5; comorbidity of cardiovascular diseases (CVD), including coronary artery disease, stroke, and limb amputation, 21.8%; albumin, 3.7 ± 0.4 g/dL; and hemoglobin, 10.4 ± 1.2 g/dL. During the 1-year observational period (December 2008-December 2009), 10,163 patients (7.1%) died, and 132,249 patients (92.9%) patients were alive at the end of the observation period.
All-cause mortality according to basic factors, dialysis dose, and nutrition factors at enrollment

The hazard ratios (HRs) for variables evaluated as potential predictors of mortality in all the patients are presented in Table 2. Male sex, increasing age, dialysis duration, presence of DM, and comorbidity of CVD were significant predictors of mortality. Higher dialysis dose, as assessed by single-pool Kt/V was associated with lower mortality risk. Furthermore, poorer nutritional status and increased inflammatory status, such as lower nPCR, lower serum albumin, lower hemoglobin, lower total cholesterol, lower BMI, lower %CGR, and higher CRP were also associated with higher mortality rate in patients on hemodialysis.

Table 1. Demographic, clinical, and laboratory values in 142,412 hemodialysis patients.

| Variables                        | All patients |
|----------------------------------|--------------|
| n                                | 142,412      |
| Age (years)                      | 64.8 ± 12.3  |
| Sex (% female)                   | 39.1         |
| HD duration (years) *            | 7 [4–12]     |
| 2–5 years (%)                    | 32.0         |
| 5–10 years (%)                   | 32.8         |
| 10–15 years (%)                  | 26.5         |
| 15–20 years (%)                  | 8.5          |
| 20–25 years (%)                  | 5.0          |
| 25–30 years (%)                  | 3.2          |
| ≥ 30 years (%)                   | 2.0          |
| Characteristics of dialyzers (%)|              |
| Low flux                         | 0.7          |
| High flux                        | 99.3         |
| Surface area of dialyzers (m²)   | 1.69 ± 0.34  |
| Presence of DM (%)               | 30.8         |
| Comorbidity of CVD (%)           | 21.8         |
| Body mass index (kg/m²)          | 21.1 ± 3.5   |
| Hemoglobin (g/dL)                | 10.4 ± 1.2   |
| Serum albumin (g/dL)             | 3.7 ± 0.4    |
| Total cholesterol (mg/dL)        | 153 ± 36     |
| Calcium (mg/dL)                  | 9.1 ± 0.8    |
| Phosphate (mg/dL)                | 5.3 ± 1.4    |
| β₂-microglobulin (mg/L)          | 27.5 ± 6.7   |
| C-reactive protein (mg/dL)       | 0.11 [0.05–0.37] |
| Kt/V                             | 1.43 ± 0.29  |
| nPCR (g/kg/day)                  | 0.89 ± 0.18  |
| %CGR (%)                         | 100 ± 25     |

* Ranges are inclusive on the lower end and exclusive on the upper end.
CVD, cardiovascular disease; nPCR, normalized protein catabolic rate; %CGR, % creatinine generation rate.

https://doi.org/10.1371/journal.pone.0184424.t001
Table 2. HRs and 95% CIs for variables evaluated as potential predictors of mortality among all the patients.

| Factors                          | HR   | 95% CI       | P value |
|----------------------------------|------|--------------|---------|
| Sex                              |      |              |         |
| Male                             | 1.00 | Reference    | Reference |
| Female                           | 0.90 | 0.86–0.94    | <0.0001 |
| Age                              |      |              |         |
| 1 year increase                  | 1.07 | 1.06–1.07    | <0.0001 |
| Hemodialysis duration (years) a |      |              |         |
| 2–5 years (%)                    | 0.93 | 0.89–0.98    | 0.003   |
| 5–10 years (%)                   | 1.00 | Reference    | Reference |
| 10–15 years (%)                  | 1.12 | 1.06–1.19    | <0.0001 |
| 15–20 years (%)                  | 1.37 | 1.26–1.48    | <0.0001 |
| 20–25 years (%)                  | 1.47 | 1.32–1.63    | <0.0001 |
| 25–30 years (%)                  | 1.37 | 1.21–1.56    | <0.0001 |
| ≥ 30 years (%)                   | 1.22 | 1.05–1.41    | 0.008   |
| Presence of DM                  |      |              |         |
| non-DM                           | 1.00 | Reference    | Reference |
| DM                               | 1.53 | 1.47–1.59    | <0.0001 |
| Comorbidity of CVD              |      |              |         |
| No comorbidity of CVD           | 1.00 | Reference    | Reference |
| Comorbidity of CVD              | 1.60 | 1.53–1.67    | <0.0001 |
| Hemoglobin                       |      |              |         |
| 1 g/dL increase                  | 0.89 | 0.87–0.90    | <0.0001 |
| C-reactive protein               |      |              |         |
| 1 mg/dL increase                 | 1.10 | 1.09–1.11    | <0.0001 |
| Kt/V a                           |      |              |         |
| <0.8                             | 2.26 | 1.91–2.67    | <0.0001 |
| 0.8–1.0                          | 1.50 | 1.37–1.65    | <0.0001 |
| 1.0–1.2                          | 1.17 | 1.10–1.24    | <0.0001 |
| 1.2–1.4                          | 1.00 | Reference    | Reference |
| 1.4–1.6                          | 0.98 | 0.93–1.03    | 0.442   |
| 1.6–1.8                          | 0.91 | 0.86–0.97    | 0.005   |
| 1.8–2.0                          | 0.86 | 0.78–0.94    | 0.001   |
| ≥ 2.0                            | 0.79 | 0.70–0.89    | <0.0001 |
| Normalized protein catabolic rate (g/kg/day) a |      |              |         |
| <0.5                             | 2.86 | 2.49–3.28    | <0.0001 |
| 0.5–0.7                          | 1.39 | 1.31–1.47    | <0.0001 |
| 0.7–0.9                          | 1.00 | Reference    | Reference |
| 0.9–1.1                          | 0.92 | 0.87–0.96    | 0.00020 |
| 1.1–1.3                          | 0.82 | 0.77–0.89    | <0.0001 |
| ≥ 1.3                            | 0.95 | 0.82–1.11    | 0.546   |
| Serum albumin (g/dL) a           |      |              |         |
| < 3.0                            | 3.86 | 3.62–4.12    | <0.0001 |
| 3.0–3.5                          | 1.72 | 1.64–1.81    | <0.0001 |
| 3.5–4.0                          | 1.00 | Reference    | Reference |
| 4.0–4.5                          | 0.86 | 0.81–0.91    | <0.0001 |
| ≥ 4.5                            | 1.03 | 0.87–1.20    | 0.757   |
| Calcium (mg/dL) a                |      |              |         |
| < 8.5                            | 1.30 | 1.23–1.37    | <0.0001 |

(Continued)
Clinical and demographic characteristics according to type of dialyzer membrane material

The patients were divided into seven groups according to the dialyzer membrane material. The demographics and characteristics of each group are shown in Table 3. More than half of the patients (56.0%) underwent hemodialysis with PS membrane, followed by CTA (17.3%),
PES (12.0%), PEPA (7.5%), PMMA (4.9%), PAN (1.2%), and EVAL (1.1%). The patients treated with EVAL showed the following features: older age, fewer males, shorter hemodialysis duration, higher rate of CVD comorbidity, and poor nutritional status. Conversely, the patients treated with PS and PES were associated with younger age, more males, lower rates of presence of diabetes and CVD, and higher Kt/V, nPCR, %CGR, and higher surface area of membrane.

Table 3. Demographic, clinical, and laboratory values in 142,412 according to type of dialyzer membrane.

|                  | CTA   | EVAL  | PAN   | PEPA  | PES   | PMMA  | PS    | P value |
|------------------|-------|-------|-------|-------|-------|-------|-------|---------|
| n (%)            | 24,572 (17.3) | 1,604 (1.1) | 1,703 (1.2) | 10,677 (7.5) | 17,060 (12.0) | 6,954 (4.9) | 79,842 (56.0) |         |
| Total deaths (n) | 2,167 | 270   | 144   | 889   | 951   | 603   | 5,139 |         |
| Death rate (per 100 patient-years) | 8.82 | 16.8  | 8.45  | 8.33  | 5.57  | 8.67  | 6.44  | <0.0001 |
| Age (years)      | 67 ± 12 | 72 ± 11 | 67 ± 12 | 66 ± 12 | 63 ± 12 | 68 ± 12 | 64 ± 12 | <0.0001 |
| Sex (% female)   | 39.5  | 55.7  | 46.7  | 41.4  | 35.2  | 43    | 38.7  | <0.0001 |
| Dialysis duration (years) | 6 [3–10] | 5 [3–9] | 7 [4–12] | 6 [3–11] | 7 [4–13] | 6 [4–11] | 7 [4–13] | <0.0001 |
| Presence of DM (%) | 35.7 | 35.5  | 31.4  | 32.3  | 28.6  | 33.2  | 29.2  | <0.0001 |
| Comorbidity of CVD (%) | 26.7  | 33.8  | 24.7  | 25.6  | 22.4  | 28.8  | 23.9  | <0.0001 |
| Body mass index (kg/m²) | 21.0 ± 3.6 | 20.0 ± 3.4 | 20.7 ± 3.3 | 20.9 ± 3.4 | 21.4 ± 3.5 | 20.6 ± 3.2 | 21.1 ± 3.5 | <0.0001 |
| Hemoglobin (g/dL) | 10.4 ± 1.3 | 10.2 ± 1.3 | 10.2 ± 1.2 | 10.4 ± 1.3 | 10.5 ± 1.2 | 10.2 ± 1.2 | 10.5 ± 1.2 | <0.0001 |
| Serum albumin (g/dL) | 3.7 ± 0.4  | 3.5 ± 0.5  | 3.7 ± 0.4  | 3.6 ± 0.4  | 3.8 ± 0.4  | 3.6 ± 0.4 | 3.7 ± 0.4 | <0.0001 |
| Total cholesterol (mg/dL) | 155 ± 36 | 162 ± 40 | 153 ± 35 | 157 ± 37 | 152 ± 35 | 162 ± 38 | 151 ± 36 | <0.0001 |
| Calcium (mg/dL)    | 9.0 ± 0.8  | 8.9 ± 0.8  | 9.1 ± 0.9  | 9.0 ± 0.8  | 9.1 ± 0.8  | 8.9 ± 0.8 | 9.1 ± 0.8 | <0.0001 |
| Phosphate (mg/dL)  | 5.3 ± 1.4  | 5.0 ± 1.4  | 5.3 ± 1.5  | 5.3 ± 1.4  | 5.4 ± 1.5  | 5.2 ± 1.4 | 5.3 ± 1.4 | <0.0001 |
| β2-microglobulin (mg/L) | 27.8 ± 7.0 | 29.8 ± 8.0 | 30.0 ± 7.0 | 27.1 ± 6.5 | 27.2 ± 6.5 | 29.5 ± 7.0 | 27.2 ± 6.5 | <0.0001 |
| C-reactive protein (mg/dL) | 0.13 [0.06–0.4] | 0.16 [0.06–0.59] | 0.13 [0.06–0.39] | 0.12 [0.05–0.38] | 0.10 [0.05–0.31] | 0.13 [0.05–0.40] | 0.11 [0.05–0.36] | <0.0001 |
| Surface area of dialyzer (m²) | 1.6 ± 0.4  | 1.4 ± 0.3  | 1.4 ± 0.2  | 1.6 ± 0.3  | 1.8 ± 0.3  | 1.6 ± 0.3 | 1.7 ± 0.3 | <0.0001 |
| Characteristic of dialyzer (%) |         |         |         |         |         |         |         | <0.0001 |
| Low flux          | 1.7    | 36.1   | 0      | 0      | 0      | 1.0    | 0      |         |
| High flux         | 98.3   | 63.9   | 100    | 100    | 100    | 99.0   | 100    |         |
| Kt/V              | 1.41 ± 0.28 | 1.30 ± 0.28 | 1.39 ± 0.29 | 1.42 ± 0.28 | 1.46 ± 0.29 | 1.39 ± 0.27 | 1.45 ± 0.29 | <0.0001 |
| nPCR (g/kg/day)   | 0.87 ± 0.18 | 0.85 ± 0.18 | 0.88 ± 0.18 | 0.88 ± 0.18 | 0.90 ± 0.18 | 0.86 ± 0.18 | 0.90 ± 0.18 | <0.0001 |
| %CGR (%)          | 97 ± 26 | 85 ± 30 | 96 ± 27 | 99 ± 26 | 102 ± 24 | 96 ± 26 | 101 ± 25 | <0.0001 |

CTA, cellulose triacetate; CVD, cardiovascular disease; DM, diabetes mellitus; EVAL, ethylene vinyl alcohol; nPCR, normalized protein catabolic rate; PAN, polyacrylonitrile; PEPA, polyester polymer alloy; PES, polyethersulfone; PMMA, polymethylmethacrylate; PS, polysulfone, %CGR, % creatinine generation rate.

https://doi.org/10.1371/journal.pone.0184424.t003
All-cause mortality according to type of dialyzer membrane material

Unadjusted all-cause mortality HRs for CTA, EVAL, PAN, PEPA, and PMMA groups, as compared with the PS group (reference), were 1.39 (1.32–1.46), 2.78 (2.45–3.14), 1.32 (1.12–1.56), 1.30 (1.21–1.40), and 1.36 (1.25–1.48), respectively (S3 Table). In contrast, only the PES group had a significantly lower HR of 0.86 (0.80–0.92) compared with the PS group (reference). Fig 2 shows adjusted all-cause mortality HRs for each group. After adjusting for basic factors, five groups had higher HRs as compared with the PS group, as well as in the unadjusted model. However, there was no significant difference between the PES and PS groups. After adjusting for dialysis-related factors, such as dialysis dose and high- or low-flux membrane in addition to basic factors, the higher HRs for the CTA, EVAL, and PEPA groups persisted. However, there were no significant differences in the HRs of the PAN and PMMA groups as compared with the PS group. Finally, after adjusting for nutrition and inflammation factors in addition to basic factors and dialysis-related factors, there were no significant differences in the HRs of the CTA, EVAL, PAN, and PEPA groups compared with the PS group. However, HRs for the PES and PMMA groups were significantly lower than that for the PS group.
Propensity score matching analysis for all-cause mortality according to type of dialyzer membrane material

Table 4 shows patient characteristics and baseline data in the PS and each corresponding group after propensity score matching. No significant differences were noted in all variables. As shown in Fig 3, HRs of CTA, EVAL, PEPA, and PES groups did not differ significantly compared with the PS group. The HR for the PMMA group (0.82 [0.71–0.94]) was significantly lower than that for the PS group (P < 0.01).

Discussion

In this study, we first confirmed the predictors for 1-year mortality in hemodialysis patients. As reported previously, basic factors such as male sex, dialysis duration, increasing age, dialysis duration, and presence of diabetes and comorbidity of CVD were included as predictors [16,17]. In addition, dialysis-related factors and nutritional- and inflammation-factors were also included as predictors. Second, we compared the mortality rate between seven types of dialyzers membrane materials adjusted for these predicting factors. After fully adjusting for these factors and propensity score matching, the HR for the PMMA membrane group was significantly lower than that for the PS membrane group used as a reference. This is the first study to suggest that the mortality risk for hemodialysis patients might differ by the type of dialyzer membrane material used.

Several cross-sectional and cohort studies have shown that efficiency of removal of small uremic toxins during each dialysis session, particularly the normalized urea clearance (Kt/V), is a useful prognostic factor in dialysis patients. These studies evaluated the role of targeting Kt/V in reducing the mortality rate [18–20]. Furthermore, Kt/V was recently identified as an independent prognostic factor following an analysis by the JRDR [1]. In these patients, nutritional status is an important prognostic factor and has shown potential as a prognostic index in medium- to long-term dialysis. Another independent prognostic factor is the estimated muscle mass from %CGR [13]. In dialysis patients, malnutrition is a complex disorder complicated by uremic toxin accumulation, weak inflammatory response due to poor membrane biocompatibility, anorexia, and loss of glucose, amino acids, and other essential nutrients during dialysis [21]. Thus, thorough assessment of treatment effects is requisite. This can be achieved by monitoring medium- to long-term indices, including maintenance levels of uremic toxins (predialysis serum β2M concentration) and nutritional status, including nPCR, serum albumin, BMI, and %CGR; these are well established indices of dialysis dose and prognosis. Although higher total cholesterol was associated with increased mortality in hemodialysis patients without a history of coronary artery disease, lower total cholesterol was associated with increased mortality in patients both with and without a history of coronary artery disease [22]. Furthermore, the presence of protein energy wasting and/or inflammation may explain the paradoxical association between total cholesterol and mortality risk in the dialysis population, because total cholesterol levels are decreased in such conditions [23]. Although lower total cholesterol levels were associated with higher mortality in the present study, care should be taken regarding the interpretation of this result since we could not collect data on the use of statins.

To minimize the inflammatory responses, it is important to select highly biocompatible membranes and purified dialysate. Several guidelines also discourage the use of dialysis membranes that promote rapid activation of the complement system, leukocytosis, and inflammatory response [3,4]. MacLeod et al. conducted a meta-analysis, which failed to establish the superiority of synthetic polymer membranes [24]. However, comparison between high-flux and low-flux membranes in a randomized controlled trial reported better prognosis with the
Table 4. Baseline characteristics after propensity score matching between PS and other groups.

|                | CTA   | PS    | P value | EVAL  | PS    | P value | PAN   | PS    | P value | PEPA  | PS    | P value | PES   | PS    | P value | PMMA  | PS    | P value |
|----------------|-------|-------|---------|-------|-------|---------|-------|-------|---------|-------|-------|---------|-------|-------|---------|-------|-------|---------|
| n (%)          | 10,592| 10,592| 0.971   | 797   | 10,592| 0.971   | 794   | 764   | 0.4883  | 4,683 | 7,480 | 0.4883  | 7,480 | 3,835 | 0.764   | 42.6  | 42.9  | 0.764   |
| Age (years)    | 67 ± 12| 67 ± 12| 0.539   | 70 ± 11| 66 ± 12| 0.089   | 66 ± 12| 66 ± 12| 0.283  | 66 ± 12| 62 ± 12| 0.283   | 62 ± 12| 0.895  | 68 ± 11| 0.091  |
| Sex (% Female) | 38 ± 6 | 37 ± 6 | 0.356   | 39 ± 4 | 52 ± 3 | 0.035   | 40 ± 8 | 41 ± 6| 0.406   | 40 ± 8 | 35 ± 8 | 0.406   | 35 ± 8| 0.635  | 42.6   | 42.9  | 0.635  |
| HD duration (years) | 6[3–10]  | 6[3–10]  | 0.964   | 5[3–9] | 6[4–11]| 0.363   | 6[4–11]| 6[4–11]| 0.978  | 6[4–11]| 7[4–12]| 0.978   | 7[4–12]| 0.931  | 6[3–11]| 6[4–11]| 0.931  |
| Presence of DM | 37.2  | 36.5  | 0.339   | 36.4  | 53.4  | 0.635   | 40.9  | 40.9  | 0.835   | 40.9  | 35.8  | 0.835   | 35.8  | 0.528  | 42.6   | 42.9  | 0.528  |
| BMI (kg/m²)    | 21.1 ± 3.6| 21.1 ± 3.5| 0.055   | 20.2 ± 3.4| 20.1 ± 3.5| 0.662   | 20.8 ± 3.3| 20.8 ± 3.3| 0.487  | 20.8 ± 3.3| 21.4 ± 3.5| 0.487   | 21.4 ± 3.6| 0.442  | 20.5 ± 3.2| 0.859  |
| Hb (g/dL)      | 10.5 ± 1.2| 10.5 ± 1.2| 0.669   | 10.3 ± 1.6| 10.4 ± 1.3| 0.946   | 10.4 ± 1.2| 10.4 ± 1.2| 0.919  | 10.5 ± 1.2| 10.5 ± 1.2| 0.712   | 10.2 ± 1.2| 10.3 ± 1.2| 0.142  |
| ALP (mg/dL)    | 3.6 ± 0.4| 3.6 ± 0.5| 0.072   | 3.5 ± 0.6| 3.5 ± 0.5| 0.885   | 3.6 ± 0.4| 3.6 ± 0.4| 0.247  | 3.6 ± 0.4| 3.6 ± 0.4| 0.247   | 3.8 ± 0.4| 3.8 ± 0.4| 0.922  | 3.6 ± 0.4| 0.921  |
| TC (mg/dL)     | 150 ± 36| 150 ± 36| 0.230   | 158 ± 39| 157 ± 36| 0.465   | 157 ± 36| 157 ± 36| 0.465  | 157 ± 36| 150 ± 33| 0.465   | 153 ± 34| 0.367  | 160 ± 37| 0.183  |
| Ca (mg/dL)     | 9.0 ± 0.8| 9.0 ± 0.8| 0.058   | 8.9 ± 0.8| 9.0 ± 0.8| 0.517   | 9.0 ± 0.8| 9.0 ± 0.8| 0.517  | 9.0 ± 0.8| 9.1 ± 0.8| 0.517   | 9.1 ± 0.8| 0.528  | 8.9 ± 0.8| 0.604  |
| P (mg/dL)      | 5.3 ± 1.4| 5.3 ± 1.4| 0.053   | 5.0 ± 1.4| 5.0 ± 1.4| 0.664   | 5.3 ± 1.4| 5.3 ± 1.4| 0.641  | 5.3 ± 1.4| 5.4 ± 1.5| 0.641   | 5.4 ± 1.5| 0.901  | 5.2 ± 1.4| 0.662  |
| BUN (mg/dL)    | 27.8 ± 7.0| 27.8 ± 6.8| 0.414   | 29.4 ± 7.7| 29.4 ± 8.4| 0.731   | 27.2 ± 6.5| 27.0 ± 6.3| 0.197  | 27.2 ± 6.5| 27.2 ± 6.2| 0.197   | 27.2 ± 6.2| 0.961  | 29.3 ± 6.9| 0.574  |
| CRP (mg/dL)    | 0.13 [0.05–0.40]| 0.13 [0.05–0.38]| 0.530   | 0.13 [0.05–0.43]| 0.059   | 0.11 [0.05–0.32]| 0.583   | 0.11 [0.05–0.32]| 0.583   | 0.11 [0.05–0.30]| 0.583   | 0.11 [0.05–0.30]| 0.583   | 0.12 [0.06–0.49]| 0.14 [0.06–0.41]| 0.691  |
| Ht/V           | 1.43 ± 0.27| 1.43 ± 0.29| 0.191   | 1.34 ± 0.26| 1.34 ± 0.27| 0.501   | 1.44 ± 0.27| 1.45 ± 0.29| 0.501  | 1.44 ± 0.27| 1.47 ± 0.29| 0.496   | 1.40 ± 0.27| 1.40 ± 0.27| 0.832  |
| nPCR (g/kg/day) | 0.87 ± 0.17| 0.87 ± 0.17| 0.858   | 0.84 ± 0.17| 0.83 ± 0.17| 0.649   | 0.88 ± 0.17| 0.88 ± 0.17| 0.672  | 0.88 ± 0.17| 0.89 ± 0.18| 0.512   | 0.86 ± 0.17| 0.85 ± 0.18| 0.125  |
| %CGR (%)       | 98 ± 36| 98 ± 26| 0.063   | 87 ± 27| 87 ± 28| 0.975   | 100 ± 26| 100 ± 29| 0.975  | 103 ± 24| 103 ± 27| 0.947   | 96 ± 26| 0.947  | 96 ± 26| 0.621  |

Alb, serum albumin; β2M, β-2 microglobulin; BMI, body mass index; Ca, calcium; CRP, C-reactive protein; CTA, cellulose triacetate; CVD, cardiovascular disease; DM, diabetes mellitus; EVAL, ethylene vinyl alcohol; nPCR, normalized protein catabolic rate; P, phosphate; PAN, polyacrylonitrile; PEPA, polyester polymer alloy; PES, polyethersulfone; PMMA, polymethylmethacrylate; PS, polysulfone; %CGR, % creatinine generation rate.

https://doi.org/10.1371/journal.pone.0184424.t004
The use of high-flux membranes for hemodialysis patients with diabetic nephropathy and patients with serum albumin <4.0 g/dL [25]. Furthermore, the mortality rate is lower for patients with predialysis serum β2M concentrations of 27.5–34 mg/L, as reported by the HEMO study and Okuno et al., suggesting that the decrease in concentrations of uremic substances, including β2M, is important in dialysis therapy [26–28]. The JRDR report states that predialysis serum β2M concentration was <30 mg/L in about 71% of patients [1].

In Japan, the HPM concept became popular around the early 1980s. Membranes with a high ultrafiltration rate, including high-flux membranes and high-permeability membranes, were considered high-efficiency membranes in the past. However, low-molecular-weight proteins that are smaller than albumin have been focused on as uremic toxins, and β2M was identified as the amyloid precursor protein in dialysis-related amyloidosis (DRA) in 1985 [29]. Therefore, dialyzers that function to eliminate solutes by adsorption and those with high biocompatibility that reduce inflammatory response are also considered to be HPM dialyzers.

HPM dialyzers have much higher biocompatibility and eliminate solutes that cannot otherwise be removed.
be eliminated by conventional dialyzers, thus, they are predicted to have favorable long-term clinical outcomes for hemodialysis patients. These include improved prognosis, and ameliorating conditions like malnutrition, DRA-associated syndromes, renal anemia, pruritus, and restless leg syndrome [30–34]. Several dialyzers currently in use can efficiently eliminate low-molecular-weight proteins; in Japan, the standard definition for HPM dialyzers is those membranes providing $\beta_2$M clearance of at least 10 mL/min in actual clinical use [1,5]. The present study showed the PMMA membrane might be superior to other HPMs in terms of mortality, because 99.3% of the patients were treated with HPMs in the present study. PMMA is a symmetric membrane, in which the whole thickness is involved in the separation process, allowing high-efficiency adsorption of both middle- and high-molecular-weight molecules such as $\beta_2$M and free light chains, and inflammatory cytokines [35–37]. Masakane reported that the body weights of patients for whom the dialyzer membrane was changed from PMMA to PS tended to decrease, while a reverse tendency was observed when the membrane was changed from PS to PMMA [38]. Similarly, Kreusser et al. reported that the cumulative 5-year survival rate for dialysis patients treated with the PMMA membrane is higher than that of patients treated with the PS membrane (68% vs. 54%) [39]. However, further long-term prospective large-scale studies are required to confirm these findings since the abovementioned studies had small sample sizes.

This study has several limitations. First, because of the nature of any annual survey and observational cohort study, the numbers of the patients differed between the seven groups. Therefore, mortality may vary between centers due to differences in center practices and patient populations. Second, we confirmed that all patients used the same membranes for 1 year after inclusion, but by the end of the study we did not have information about the types of dialyzers used. To investigate outcomes associated with the use of different dialyzers, further long-term studies with matched baseline characteristics of the patients are needed. However, we consider that the present study revealed and matched the actual clinical setting for hemodialysis treatment in Japan. Finally, we had no information about residual renal function, which could be a possible confounder. However, since the reported loss of renal function after starting dialysis was about 2.0 mL/min/year [40] and the mean estimated glomerular filtration rate at dialysis initiation was 6.52 mL/min/1.73 m$^2$ in 2007 throughout Japan [41], the impact of residual renal function may be negligible because the median dialysis duration was 7 years in our cohort.

The results of this study suggest that the use of different membrane material types may have an impact on mortality in hemodialysis patients. However, further long-term prospective studies are needed to clarify these findings, including whether the PMMA membrane can improve prognosis.

Supporting information
S1 Table. Class according to the Japanese reimbursement system.
(DOCX)

S2 Table. Characteristics of the high-performance membrane dialyzers available in the present study. All data were provided by the manufacturer. a Plasma was used as a pseudo blood in the experiment. b Clearances were measured under the following conditions: blood flow rate = 200 mL/min, dialysis fluid flow rate = 500 mL/min, and ultrafiltration flow rate per unit surface area = 10 mL/min/m$^2$. CTA, cellulose triacetate; EVAL, ethylene vinyl alcohol; PAN, polyacrylonitrile; PEPA, polyester polymer alloy; PES, polyethersulfone; PMMA, polymethylmethacrylate; PS, polysulfone.
(DOCX)
S3 Table. HRs (95% CIs) of all-cause mortality between seven types of dialyzers in 142,412 maintenance hemodialysis patients using standard Cox proportional hazards regression.

\(^a\)Adjusted for age, sex, dialysis duration, presence or absence of diabetes and cardiovascular disease. \(^b\)Adjusted for basic factors and \(\text{Kt/V}\). \(^c\)Adjusted for basic factors, \(\text{Kt/V}\), normalized protein catabolic rate, serum albumin, total cholesterol, body mass index, and \% creatinine generation rate. CI, confidence interval; CTA, cellulose triacetate; EVAL, ethylene vinyl alcohol; HR, hazard ratio; PAN, polyacrylonitrile; PEPA, polyester polymer alloy; PES, polyethersulfone; PMMA, polymethylmethacrylate; PS, polysulfone.

(DOCX)

S1 File. Data set of all patients who were included in the final cohort. Alb, serum albumin; \(\beta_2\)-microglobulin; BMI, body mass index; Ca, serum calcium; CRP, C-reactive protein; CTA, cellulose triacetate; EVAL, ethylene vinyl alcohol; Hb, hemoglobin; HD, hemodialysis; nPCR, normalized protein catabolic rate; P, serum phosphate; PAN, polyacrylonitrile; PEPA, polyester polymer alloy; PES, polyethersulfone; PMMA, polymethylmethacrylate; PS, polysulfone; \%CGR, \% creatinine generation rate; TC, total cholesterol.

(ZIP)

Acknowledgments

Japanese Society for Dialysis Therapy

President

Hidetomo Nakamoto, MD

JSDT Renal Data Registry (JRDR) Committee

Chief

Ikuto Masakane, MD

Research Subcommittee of JRDR

Takayuki Hamano, MD; Eiichiro Kanda, MD; Masanori Abe, MD; Takehiko Kawaguchi, MD; Kan Kikuchi, MD; Shunsuke Goto, MD; Yusuke Sakaguchi, MD; Naohiko Fujii, MD; Kichihiro Fujisaki, MD; Junichi Hoshino, MD; Yukio Maruyama, MD; Mariko Miyazaki, MD; Minako Wakasugi, MD; Hirokata Komaba, MD; Minoru Murakami, MD; Kaoru Yasuda, MD.

We thank the participants in the dialysis registry of the Japanese Society for Dialysis Therapy, the JSDT Renal Data Registry Committee, and all personnel at the institutions that participated in this survey.

Author Contributions

Conceptualization: Masanori Abe, Ikuto Masakane.

Data curation: Masanori Abe, Takayuki Hamano, Atsushi Wada, Shigeru Nakai.

Formal analysis: Masanori Abe.

Investigation: Masanori Abe, Ikuto Masakane.

Methodology: Masanori Abe, Takayuki Hamano.

Project administration: Masanori Abe, Atsushi Wada, Shigeru Nakai.

Resources: Masanori Abe, Atsushi Wada.

Software: Masanori Abe.

Supervision: Takayuki Hamano, Ikuto Masakane.
Validation: Masanori Abe.
Visualization: Masanori Abe.
Writing – original draft: Masanori Abe.
Writing – review & editing: Masanori Abe, Takayuki Hamano, Atsushi Wada, Shigeru Nakai, Ikuto Masakane.

References
1. Watanabe Y, Kawanishi H, Suzuki K, Nakai S, Tsuchida K, Tabei K, et al. “Maintenance Hemodialysis: Hemodialysis Prescriptions” Guideline Working Group, Japanese Society for Dialysis Therapy. Japanese society for dialysis therapy clinical guideline for “Maintenance hemodialysis: Hemodialysis prescriptions”. Ther Apher Dial. 2015; 19(Suppl 1): 67–92.
2. Saito A. Definition of high-performance membranes–from the clinical point of view. Contrib Nephrol 2011; 173: 1–10. https://doi.org/10.1159/000328938 PMID: 21865779
3. National Kidney Foundation: Clinical practice guidelines for hemodialysis adequacy. Am J Kidney Dis 2006; 48(Suppl 1): s12–s47.
4. Tattersall J, Martin-Malo A, Pedrini L, Basci A, Canaud B, Fouque D, et al. EBPG guideline on dialysis strategies. Nephrol Dial Transplant 2007; 22(Suppl 2): ii5–21.
5. Yamashita AC. Mass transfer mechanisms in high-performance membrane dialyzers. Contrib Nephrol 2011; 173: 95–102. https://doi.org/10.1159/000328946 PMID: 21865781
6. Nakai S, Iseki K, Itami N, Ogata S, Kazama JJ, Kimata N, et al. An overview of regular dialysis treatment in Japan (as of 31 December 2010). Ther Apher Dial 2012; 16: 483–521. https://doi.org/10.1111/j.1744-9987.2012.01143.x PMID: 23190510
7. Iseki K, Nakai S, Yamagata K, Tsubakihara Y. Committee of Renal Data Registry of the Japanese Society for Dialysis Therapy: Tachycardia as a predictor of poor survival in chronic haemodialysis patients. Nephrol Dial Transplant 2011; 26: 963–969. https://doi.org/10.1093/ndt/gfq507 PMID: 20817672
8. Masakane I, Takemoto Y, Nakai S, Tsubakihara Y, Akiba T, Watanabe Y, et al. Bacteriological water quality in the central dialysis fluid delivery system from the survey of the Japanese Society for Dialysis Therapy. Blood Purif 2009; 27(Suppl 1): 11–16.
9. Masakane I, Nakai S, Ogata S, Kimata N, Hamano T, et al. An Overview of Regular Dialysis Treatment in Japan (As of 31 December 2013). Ther Apher Dial 2015; 19: 540–574. https://doi.org/10.1111/1744-9987.12378 PMID: 26768810
10. Nakai S, Suzuki K, Masakane I, Wada A, Itami N, Ogata S, et al. An Overview of Regular Dialysis Treatment in Japan (As of 31 December 2008). Ther Apher Dial 2010; 14: 505–540. https://doi.org/10.1111/j.1744-9987.2010.00893.x PMID: 21118359
11. Nakai S, Iseki K, Itami N, Ogata S, Kazama JJ, Kimata N, et al. An Overview of Regular Dialysis Treatment in Japan (As of 31 December 2009). Ther Apher Dial 2012; 16: 11–53. https://doi.org/10.1111/j.1744-9987.2011.01050.x PMID: 22248195
12. Shinzato T, Nakai S, Fujita Y, Takai I, Morita H, Nakane K, et al. Determination of Kt/V and protein catabolic rate using pre- and postdialysis blood urea nitrogen concentrations. Nephron 1994; 67: 280–290. PMID: 7936017
13. Shinzato T, Nakai S, Miwa M, Iwayama N, Takai I, Matsumoto Y, et al. New method to calculate creatinine generation rate using pre- and postdialysis creatinine concentrations. Artif Organs 1997; 21: 864–872. PMID: 9247176
14. Lin YC, Lin YC, Hsu CY, Kao CC, Chang FC, Chen TW, Chen HH, Hsu CC, Wu MS. Taiwan Society of Nephrology. Effect modifying role of serum calcium on mortality-predictability of PTH and alkaline phosphatase in hemodialysis patients: An investigation using data from the Taiwan Renal Registry Data System from 2005 to 2012. PLoS One. 2015 Jun 24; 10(6):e0129737.
15. Liu CT, Lin YC, Kao CC, Chen HH, Hsu CC, Wu MS. Roles of serum calcium, phosphorus, PTH and ALP on mortality in peritoneal dialysis patients: A Nationwide, Population-based Longitudinal Study Using TWRDS 2005–2012. Sci Rep 2017; 7: 33.
16. Kopple JD, Zhu X, Lew NL, Lowrie EG. Body weight for height relationships predict mortality in maintenance hemodialysis patients. Kidney Int 1999; 56: 1136–1148. https://doi.org/10.1046/j.1523-1755.1999.00615.x PMID: 10469384
17. Lowrie EG, Laird NM, Parker TF, Sargent JA. Effect of the hemodialysis prescription of patient morbidity. Report from the National Cooperative Dialysis Study. N Engl J Med 1981; 305: 1176–1181. https://doi.org/10.1056/NEJM1981111123052900 PMID: 7027040
18. Shinzato T, Nakai S, Akiba T, Yamazaki C, Sasaki R, Kitaoka T, et al. Survival in long-term haemodialysis patients: results from the annual survey of the Japanese Society for Dialysis Therapy. Nephrol Dial Transplant 1997; 12: 884–888. PMID: 9175039

19. Collins AJ, Ma JZ, Umen A, Keshaviah P. Urea index and other predictors of hemodialysis patient survival. Am J Kidney Dis 1994; 23: 272–282. PMID: 8311087

20. Hakim RM, Breyer J, Ismail N, Schulman G. Effects of dose of dialysis on morbidity and mortality. Am J Kidney Dis 1994; 23: 661–669. PMID: 8172208

21. Stenvinkel P, Heimburger O, Paultre F, Diczfalusi U, Wang T, Berglund L, et al. Strong association between malnutrition, inflammation, and atherosclerosis in chronic renal failure. Kidney Int 1999; 55: 1899–1911. https://doi.org/10.1046/j.1523-1755.1999.00422.x PMID: 10231453

22. Lin YC, Lin YC, Chen HH, Chen TW, Hsu CC, Wu MS. Different effect of hypercholesterolemia on mortality in hemodialysis patients based on coronary artery disease or myocardial infarction. Lipids Health Dis. 2016; 15: 211. https://doi.org/10.1186/s12944-016-0380-7 PMID: 27927204

23. Shoji T, Masakane I, Watanabe Y, Iseki K, Tsubakihara Y; Committee of Renal Data Registry, Japanese Society for Dialysis Therapy. Elevated non-high-density lipoprotein cholesterol (non-HDL-C) predicts atherosclerotic cardiovascular events in hemodialysis patients. Clin J Am Soc Nephrol 2011; 6: 1112–1120. https://doi.org/10.2215/CJN.09961110 PMID: 21511840

24. MacLeod AM, Campbell M, Cody JD, Daly C, Donaldson C, Grant A, et al. Cellulose modified cellulose and synthetic membranes in the haemodialysis of patients with end-stage renal disease. Cochrane Database Syst Rev 2005; 3: CD003234.

25. Locatelli F, Martin-Malo A, Hannedouche T, Loureiro A, Papadimitriou M, Wizemann V, et al. Membrane Permeability Outcome (MPO) Study Group. Effect of membrane permeability on survival of hemodialysis patients. J Am Soc Nephrol 2009; 20: 645–654. https://doi.org/10.1681/ASN.2008060590 PMID: 19092122

26. Okuno S, Ishimura E, Kohno K, Fujino-Kato Y, Maeno Y, Yamakawa T, et al. Serum beta2-microglobulin level is a significant predictor of mortality in maintenance haemodialysis patients. Nephrol Dial Transplant 2009; 24: 571–577. https://doi.org/10.1093/ndt/gfn521 PMID: 18799606

27. Cheung AK, Rocco MV, Yan G, Leypoldt JK, Levin NW, Greene T, et al. Serum beta-2 microglobulin levels predict mortality in dialysis patients: results of the HEMO study. J Am Soc Nephrol 2006; 17: 546–555. https://doi.org/10.1681/ASN.2005020132 PMID: 16382021

28. Cheung AK, Greene T, Leypoldt JK, Yan G, Allon M, Delmez J, et al. HEMO Study Group. Association between serum 2-microglobulin level and infectious mortality in hemodialysis patients. Clin J Am Soc Nephrol 2008; 3: 69–77. https://doi.org/10.2215/CJN.02340607 PMID: 18057309

29. Gejyo F, Yamada T, Odani S, Nakagawa Y, Arakawa M, Kunitomo T, et al. A new form of amyloid protein associated with chronic hemodialysis was identified as beta 2-microglobulin. Biochim Biophys Res Commun 1985, 129: 701–706. PMID: 3893430

30. Nakai S, Iseki K, Tabei K, Kubo K, Masakane I, Fushimi K, et al. Outcomes of hemodiafiltration based on Japanese dialysis patient registry. Am J Kidney Dis 2001; 38(Suppl 1): S212–S216. PMID: 11576958

31. Koda Y, Nishi S, Miyazaki S, Haginoshita S, Sakurabayashi T, Suzuki M, et al. Switch from conventional to high-flux membrane reduces the risk of carpal tunnel syndrome and mortality of hemodialysis patients. Kidney Int 1997; 52: 1096–1101. PMID: 9328951

32. Higuchi T, Abe M, Mizuno M, Yamazaki T, Suzuki H, Moriuchi M, et al. Association of restless legs syndrome with oxidative stress and inflammation in patients undergoing hemodialysis. Sleep Med 2015; 16: 941–948. https://doi.org/10.1016/j.sleep.2015.03.025 PMID: 26070856

33. Augella F, Vigilante M, Gesuete A, Maruccio G, Specchio A, Gesualdo L. Uraemic itching: do polymethylmethacrylate dialysis membranes play a role? Nephrol Dial Transplant 2007; 22(Suppl 5): v8–v12.

34. Augella F, Gesuete A, Vigilante M, Prencipe M. Adsorption dialysis: From physical principles to clinical applications. Blood Purif 2013; 35(suppl 2): 42–47.

35. Traut M, Haufe CC, Eismann U, Deppisch RM, Stein G, Wolf G. Increased binding of beta-2-microglobulin to blood cells in dialysis patients treated with high-flux dialyzers compared with low-flux membranes contributed to reduced beta-2-microglobulin concentrations. Results of a cross-over study. Blood Purif 2007; 25: 432–440. https://doi.org/10.1159/000100689 PMID: 17957097

36. Sakai Y. Polymethylmethacrylate membrane with a series of serendipity. Contrib Nephro 2011; 73: 137–147.

37. Santoro A, Grazia M, Mancini E. The double polymethylmethacrylate filter (DELETE system) in the removal of light chains in chronic dialysis patients with multiple myeloma. Blood Purif 2013; 35 (suppl 2): 5–13.
38. Masakane I: High-quality dialysis: a lesson from the Japanese experience. NDT plus 2010; 3(suppl 1): i28–i35. https://doi.org/10.1093/ndtplus/sfq034 PMID: 27046011

39. Kreusser W, Reiermann S, Vogelbusch G, Bartual J, Schulze-Lohoff E. Effect of different synthetic membranes on laboratory parameters and survival in chronic haemodialysis patients. NDT plus 2010; 3(suppl 1): i12–i19. https://doi.org/10.1093/ndtplus/sfq032 PMID: 27046088

40. Schiffl H, Lang SM, Fischer R. Ultrapure dialysis fluid slows loss of residual renal function in new dialysis patients. Nephrol Dial Transplant 2001; 17: 1814–1818.

41. Watanabe Y, Yamagata K, Nishi S, Hirakata H, Hanafusa N, Saito C, et al. “Hemodialysis Initiation for Maintenance Hemodialysis” Guideline Working Group, Japanese Society for Dialysis Therapy: Japanese Society for Dialysis Therapy clinical guideline for “hemodialysis initiation for maintenance hemodialysis”. Ther Apher Dial 2015; 19(Suppl 1): 93–107.